News | Antiplatelet and Anticoagulation Therapies | November 14, 2016

Study Finds Blood Clot Prevention Medications Equally Safe and Effective for PCI Patients

Results find rates of major bleeding and other adverse events statistically similar with bivalirudin versus heparin with short-term tirofiban infusion

bivalirudin, heparin, blood clot prevention medication, PCI, percutaneous coronary intervention, Intermountain study, AHA Scientific Sessions

November 14, 2016 — Two differing blood clot prevention medications are just as safe and effective for patients undergoing percutaneous coronary intervention (PCI), according to a new study.

The scientific community has proposed both medications as potentially superior to longer-term anticoagulation treatments for patients undergoing the non-surgical procedure to open blood vessels narrowed by plaque buildup.

The new study by researchers from the Intermountain Medical Center Heart Institute in Salt Lake City sought to discover which of the two short-term treatment methods —using the drug heparin combined with a short-term (less than six hours) infusion of tirofiban, or short-term periprocedural bivalirudin, another medication that helps prevent blood clots during the procedure — was more effective.

Through this observational study of patients undergoing successful elective PCI, the Intermountain researchers found the risk after 30 days of major bleeding, and one-year risk of death, heart attack and urgent repeat PCI, was low and not significantly different between the two treatment methods.

Results of the study were presented during the American Heart Association Scientific Sessions, Nov. 12-16 in New Orleans.

“Bivalirudin has been considered the gold standard for reducing bleeding during percutaneous coronary intervention, but our study shows heparin plus short-term tirofiban is just as good and possibly better,” said Intermountain Medical Center Heart Institute cardiologist J. Brent Muhlestein, M.D., the lead author on the study. “The results certainly justify a randomized clinical trial to explore identified trends.”

Researchers studied results from patients who underwent PCI between January 2013 and December 2015. Of the 857 patients enrolled in the study, 402 received heparin plus short-term tirofiban treatment and 455 received bivalirudin. The patients were between the ages of 51 and 78.

There was a slight reduction in major bleeding and death with the use of heparin plus short-term tirofiban over bivalirudin alone, but due to the overall low incidence of adverse events, the difference did not reach statistical significance.

The 30-day incidence of TIMI (Thrombolysis in Myocardial Infarction) major bleeding score was 1.2 percent for patients treated with heparin and tirofiban and 3.1 percent for bivalirudin patients.

In addition to Muhlestein, other members of the Intermountain Medical Center Heart Institute research team include: Heidi T. May, Ph.D.; Tami L. Bair; Viet Le, PA-C; Jeffrey L. Anderson, M.D.; Brian Whisenant, M.D.; Kirk U. Knowlton, M.D.; and Donald L. Lappé, M.D.

For more information: www.scientificsessions.org

Related Content

Experimental Vaccine May Reduce Post-Stroke Blood Clot Risk
News | Antiplatelet and Anticoagulation Therapies | November 01, 2018
A vaccine may one day be able to replace oral blood thinners to reduce the risk of secondary strokes caused by blood...
Thrombolytic Science Initiates Phase 2 Trial of Novel Ischemic Stroke Treatment Regimen
News | Antiplatelet and Anticoagulation Therapies | September 07, 2018
A new Phase 2 clinical trial looks to confirm the efficacy and safety of Thrombolytic Science LLC’s (TSI) sequential...
Bleeds and Benefit With Aspirin Balanced in Diabetes Patients
News | Antiplatelet and Anticoagulation Therapies | September 05, 2018
Aspirin prevented serious vascular events in patients with diabetes who did not already have cardiovascular disease,...
Extended Post-Hospital Oral Anticoagulant Use Reduces Non-Fatal Blood Clots
News | Antiplatelet and Anticoagulation Therapies | August 31, 2018
Use of an oral anticoagulant in medically ill patients for 45 days following hospital discharge reduces the rate of non...
AFib Patients Want More Information About Anticoagulation Reversal
News | Antiplatelet and Anticoagulation Therapies | June 27, 2018
Results from a 902-person, five-country survey of people living with atrial fibrillation (AF) reinforce the importance...
Lower Oral DOAC Anticoagulant Use Associated With More Thromboembolic Events Than Warfarin. #HRS 2018
News | Antiplatelet and Anticoagulation Therapies | May 18, 2018
May 18, 2018 — Nearly half of patients prescribed warfarin and just under one third of those using newer direct oral
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated for patients treated with rivaroxaban (Xarelto) and apixaban (Eliquis), when reversal of anticoagulation is needed due to life-threatening or uncontrolled bleeding.

 

Feature | Antiplatelet and Anticoagulation Therapies | May 07, 2018
The U.S. Food and Drug Administration (FDA) has approved Portola Pharmaceuticals' Andexxa, the first antidote indicated...
The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association. #ACC18

The largest trial to date for short-term DAPT concluded the practice cannot be deemed safe due to a higher adverse event rate. Image courtesy of the American Heart Association.

News | Antiplatelet and Anticoagulation Therapies | March 19, 2018
The combined rate of death from any cause, heart attack or stroke within 18 months was not significantly different in...
The Xarelto booth at ACC.18

The Xarelto booth at the 2018 American College of Cardiology meeting. 

News | Antiplatelet and Anticoagulation Therapies | March 14, 2018
March 14, 2018 — A late-breaking analysis of the landmark COMPASS study presented at the American College of Cardiolo
Overlay Init